36 / 105
A
ndrade
GC
de
et
al
.
226
R
ev
A
ssoc
M
ed
B
ras
2016; 62(3):218-226
33. Mattos AA. Nonalcoholic steatohepatitis. J Bras Gastroenterol. 2005; 5:160-5.
34.
Miele L, Forgione A, Hernandez AP, Gabrieli ML, Vero V, Di Rocco P, Greco
AV, et al. The natural history and risk factors for progression of non-alcoholic
fatty liver disease and steatohepatitis. Eur Rev Med Pharmacol Sci. 2005;
9(5):273-7.
35.
Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S. Effects
of tamoxifen on hepatic fat content and the development of hepatic steatosis
in patients with breast cancer: high frequency of involvement and rapid
reversal after completion of tamoxifen therapy. AJR Am J Roentgenol. 2003;
180(1):129-34.
36.
Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in
abetalipoproteinemia: evolution of micronodular cirrhosis. Gastroenterology.
1974; 67(1):107-18.
37.
Poucell S, Ireton J, Valencia-Mayoral P , Downar E, Larrat L, Patterson J, et
al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light,
immunohistochemical and electron microscopic studies. Gastroenterology.
1984; 86(5 Pt 1):926-36.
38.
Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The
natural history of nonalcoholic steatohepatitis: a follow-up study of forty-
two patients for up to 21 years. Hepatology. 1990; 11(1):74-80.
39.
Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb
lipodystrophy. Gastroenterology. 1989; 97(4):1022-4.
40.
Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis. Ann Intern
Med. 1995; 123(3):236.
41.
Redlich CA, West AB, Fleming L, True LD, Cullen MR, Riely CA. Clinical
and pathological characteristics of hepatotoxicity associated with
occupational exposure to dimethylformamide. Gastroenterology. 1990;
99(3):748-57.
42.
Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri
BA, Bhathal PS, et al. Progressive fibrosis in nonalcoholic steatohepatitis:
association with altered regeneration and a ductular reaction.
Gastroenterology. 2007; 133(1):80-90.
43.
Salgado Júnior W, Santos JS, Sankarankutty AK, Silva OC. Nonalcoholic
fatty liver disease and obesity. Acta Cir Bras. 2006; 21(Suppl.1):72-8.
44.
Santos RR, CotrimHP. Relevância das medidas antropométricas na avaliação
de pacientes com doença hepática gordurosa não alcoólica. Rev Bras Nutr
Clin. 2006; 21(3):229-32.
45.
Sanyal AJ; American Gastroenterological Association. AGA technical review
on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5):1705-25.
46.
Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence
of gender, race, and ethnicity on suspected fatty liver in obese adolescents.
Pediatrics. 2005; 115(5):561-5.
47.
Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, et
al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
J Hepatol. 2002; 37(1):154-60.
48.
Silverman JF, O Brien KF, Long S, Leggett N, Khazanie PG, Poris WJ, Norris
HT, et al. Liver Pathology in morbidly obese patients with and without
diabetes. Am J Gastroenterol. 1990; 85(10):1349-55.
49.
Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis. 2003;
7(2):435-51.
50.
Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis
and cryptogenic cirrhosis within kindreds. Am J Med. 2000; 108(1):9-13.
51. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up
report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26(11):3160-7.
52. Van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert
E, et al. Lipodystrophy in HIV-1 positive patients is associated with insulin
resistance in multiple metabolic pathways. AIDS. 2001; 15(16):2093-100.
53. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an
autopsy study with analysis of risk factors. Hepatology. 1990; 12(5):1106-10.
54. Wanless IR, Shiota K.The pathogenesis of nonalcoholic steatohepatitis and
other fatty liver diseases: a four-step model including the role of lipid release
and hepatic venular obstruction in the progression to cirrhosis. Semin Liver
Dis. 2004; 24(1):99-106.
55. Wasserman JM, Thung SN, Berman R, Bodenheimer HC Jr, Sigal SH. Hepatic
Weber-Christian disease. Semin Liv Dis. 2001; 21(1):115-8.
56. Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, et al. Racial
and ethnic distribution of nonalcoholic fatty liver in persons with newly
diagnosed chronic liver disease. Hepatology. 2005; 41(2):372-9.